Traduction de «effect of smoking cessation » (Néerlandais → Français) :

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

36. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.
36. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ et al. The clinical effectiveness and cost-effectiveness of Bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.

40. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial.
40. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S et al. Effectiveness of Bupropion sustained release for smoking cessation in a health care setting: a randomized trial.

patients remain on one type of treatment throughout their smoking cessation therapy costs and consequences of side-effects of bupropion or NRT were not taken into account
patients remain on one type of treatment throughout their smoking cessation therapy costs and consequences of side-effects of Buproprion or NRT were not taken into account

Smoking cessation is the most important lifestyle target for the prevention of stroke.4-6 All smokers should receive the urgent advice to stop smoking, and help in doing so is to be offered (Evidence level 1, see KCE report Vol.
Smoking cessation is the most important lifestyle target for the prevention of stroke.4-6 All smokers should receive the urgent advice to stop smoking, and help in doing so is to be offered (Evidence level 1, see KCE report Vol. 1A).

Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke [see comments].
Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke.

MeSH : Smoking Cessation ; Nicotine / therapy, drug therapy ; Bupropion ; Nortriptyline ; Antidepressive Agents ; Behavior Therapy ; Counseling ; Cost-Benefit Analysis NLM classification : WM 290
MeSH : Smoking Cessation ; Nicotine / therapy, drug therapy ; Bupropion ; Antidepressive Agents ; Behavior Therapy ; Counseling ; Cost-Benefit Analysis NLM classification : WM 290

Bron: Fichtenberg C, Glantz S, Effect of smoke-free workplaces on smoking behaviour: systematic review, BMJ, 2002; 325:188-91)
Source : Fichtenberg C, Glantz S, Effect of smoke-free workplaces on smoking behaviour: systematic review, BMJ, 2002; 325:188-91)